Kenvue Inc
Company Profile
Business description
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Contact
1 Kenvue Way
SummitNJ07901
USAT: +1 908 874-1200
Sector
Consumer Defensive
Stock type
Defensive
Industry
Household & Personal Products
Fiscal Year End
31 December 2026
Employees
22,000
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 3.60 | -0.04% |
| CAC 40 | 8,143.49 | 78.47 | 0.97% |
| DAX 40 | 25,605.62 | 301.56 | 1.19% |
| Dow JONES (US) | 52,006.48 | 323.84 | 0.63% |
| FTSE 100 | 10,766.29 | 107.16 | 1.01% |
| HKSE | 25,042.71 | 291.93 | 1.18% |
| NASDAQ | 26,522.54 | 104.25 | 0.39% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.20 | 82.06 | 0.60% |
| S&P 500 | 7,696.18 | 45.68 | 0.60% |
| S&P/ASX 200 | 8,731.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,949.91 | 38.04 | 0.97% |